Steric Stabilization of Liposomes Containing Amphotericin B: A Future Direction in Antifungal Therapy?
In the past ten years lipid formulations of amphotericin B (AMB) have been developed by the pharmaceutical industry with the primary aim of reduction of AMB’s toxicity. At present, three different industrially produced AMB-lipid formulations are available
- PDF / 34,302,336 Bytes
- 305 Pages / 439.425 x 666.172 pts Page_size
- 68 Downloads / 132 Views
Martin C. Woodle, Ph.D. • Gerrit Storm, Ph.D. (Eds.)
Long Circulating Liposomes: Old Drugs, New Therapeutics
'
Springer
Martin C. Woodle, Ph.D.
Gerrit Storm, Ph.D.
Genetic Therapy, Inc. Gaithersburg, Maryland U.S.A.
Department of Pharmaceutics University of Utrecht Utrecht, The Netherlands
Library of Congress Cataloging-in-Publication data Long circulating liposomes: old drugs, new therapeutics I [edited by] Martin C. Woodle, Gerrit Storm. p. em. - (Biotechnology intelligence unit) Includes bibliographical references and index. ISBN 978-3-662-22115-0 (eBook) ISBN 978-3-662-22117-4 DOI 10.1007/978-3-662-22115-0 1. Liposomes-Therapeutic use. 2. Drug carriers. 3. Drugs-Vehicles. I. Woodle, Martin C. II. Storm, Gerrit. III. Series. [DNLM: 1. Liposomes-therapeutic use. 2. Liposomes-Diagnostic use. 3· Drug Carriers. 4· Antineoplastic Agents-administration & dosage. QU 93 L848 1997] RS2o1.L55L66 1997 6I5'·7-dC21 97-30426 DNLM/DLC CIP for Library of Congress This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag Berlin Heidelberg GmbH. Violations are liable for prosecution under the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1998 Originally published by Springer-Verlag Berlin Heidelberg New York in 1998 Softcover reprint of the hardcover 1st edition 1998 The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher cannot guarantee the accuracy of any information about dosage and application thereof contained in this book. In every individual case the user must check such information by consulting the relevant literature. Typesetting: Landes Bioscience Georgetown, TX, U.S.A. SPIN: 10630491
31/3111- 54 3 21 o- Printed on acid-free paper
=======PREFACE=============== theme of this book is that new formulations of existing Thedrugsoverall can create entirely new therapeutic agents. The changes that
can occur impact important clinical issues such as therapeutic index, schedule, route, side effects and-most importantly-indications. Thus, the principle of using advanced formulation technology with existing or old agents to create effectively new therapeutic agents appears as one of the most promising to address the continuing need for better therapeutic agents for clinical practice. The Doxil"' and DaunoXome'" long circulating liposome formulations of well known drugs now available to clinicians are good exam
